BACKGROUND: Trivalent inactivated influenza vaccine (TIV) is not licensed for use in infants <6 months old, the group with the highest influenza hospitalization rates among children. METHODS: In this prospective, open-label study, 2 doses of TIV were administered to healthy infants aged 10-22 weeks. Adverse reactions were assessed, and hemagglutination inhibition (HAI) antibody titers were determined. Weekly telephone surveillance for influenza-like illness was conducted during the influenza season. RESULTS: A total of 42 infants were enrolled and completed the study. Mild local and systemic reactions were noted. In the first season (2004-2005), postvaccination HAI titers >1:32 were noted for 31.6%, 47.4%, and 21.1% of 19 subjects for H1N1, H3N2, and B strains included in the vaccine, respectively. In the second season (2005-2006), postvaccination HAI titers >1:32 were seen in 45.5%, 59.1%, and 0% of 23 subjects for H1N1, H3N2, and B strains included in the vaccine, respectively. Infants who were seronegative before vaccination (titers <1:8) were significantly more likely to have a 4-fold rise in antibody titer after vaccination, compared with infants who had prevaccination titers >1:8 (P<.001). CONCLUSION: Two doses of TIV were found to be safe and moderately immunogenic against some influenza strains. The presence of preexisting maternally derived antibody was associated with significantly lower seroresponse rates to vaccination. Whether vaccination with TIV will prevent influenza in these young children remains to be determined.
BACKGROUND: Trivalent inactivated influenza vaccine (TIV) is not licensed for use in infants <6 months old, the group with the highest influenza hospitalization rates among children. METHODS: In this prospective, open-label study, 2 doses of TIV were administered to healthy infants aged 10-22 weeks. Adverse reactions were assessed, and hemagglutination inhibition (HAI) antibody titers were determined. Weekly telephone surveillance for influenza-like illness was conducted during the influenza season. RESULTS: A total of 42 infants were enrolled and completed the study. Mild local and systemic reactions were noted. In the first season (2004-2005), postvaccination HAI titers >1:32 were noted for 31.6%, 47.4%, and 21.1% of 19 subjects for H1N1, H3N2, and B strains included in the vaccine, respectively. In the second season (2005-2006), postvaccination HAI titers >1:32 were seen in 45.5%, 59.1%, and 0% of 23 subjects for H1N1, H3N2, and B strains included in the vaccine, respectively. Infants who were seronegative before vaccination (titers <1:8) were significantly more likely to have a 4-fold rise in antibody titer after vaccination, compared with infants who had prevaccination titers >1:8 (P<.001). CONCLUSION: Two doses of TIV were found to be safe and moderately immunogenic against some influenza strains. The presence of preexisting maternally derived antibody was associated with significantly lower seroresponse rates to vaccination. Whether vaccination with TIV will prevent influenza in these young children remains to be determined.
Authors: H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin Journal: J Infect Dis Date: 2001-08-22 Impact factor: 5.226
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Anthony E Fiore; David K Shay; Penina Haber; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox Journal: MMWR Recomm Rep Date: 2007-07-13
Authors: Beth C Holbrook; Jong R Kim; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Ralph B D'Agostino; S Tyler Aycock; Mallinath B Hadimani; S Bruce King; Griffith D Parks; Martha A Alexander-Miller Journal: J Immunol Date: 2016-06-08 Impact factor: 5.422
Authors: Julie H Shakib; Kent Korgenski; Angela P Presson; Xiaoming Sheng; Michael W Varner; Andrew T Pavia; Carrie L Byington Journal: Pediatrics Date: 2016-05-02 Impact factor: 7.124
Authors: Jong R Kim; Beth C Holbrook; Sarah L Hayward; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Kristina De Paris; Ralph B D'Agostino; S Tyler Aycock; Steven B Mizel; Griffith D Parks; Martha A Alexander-Miller Journal: J Virol Date: 2015-05-06 Impact factor: 5.103
Authors: Marlena M Westcott; Elene A Clemens; Beth C Holbrook; S Bruce King; Martha A Alexander-Miller Journal: Vaccine Date: 2018-02-21 Impact factor: 3.641